Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232178 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant
A Phase 2 study, sponsored by Innocoll.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02232178 is a Phase 2 study that has completed, run by Innocoll. The registered enrollment target is 64 participants.
The verdict
NCT02232178, a Phase 2 study, has completed, sponsored by Innocoll.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
Interventions
- DRUG 2 100mg Xaracoll implants
- DRUG 3 100mg Xaracoll implants
- DRUG 150mg Bupivacaine HCl injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-10-20 |
| Est. Completion | 2015-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02232178
The ClinicalTrials.gov registry entry for NCT02232178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innocoll, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 2 100mg Xaracoll implants is the first listed.
NCT02232178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02232178 about?
NCT02232178 is a clinical study titled "Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant". Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
What is the current status of trial NCT02232178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-10-20. Estimated completion is 2015-03-23.
What interventions are being tested in trial NCT02232178?
The interventions under investigation include: 2 100mg Xaracoll implants (DRUG), 3 100mg Xaracoll implants (DRUG), 150mg Bupivacaine HCl injection (DRUG).
Who is sponsoring clinical trial NCT02232178?
This trial is sponsored by Innocoll, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.